Ranbaxy, Cipla look to U.S. to absorb plant capacity; Europe looks to restrict use of phthalates;

> With excess capacity and price restraints on domestic drugs, India's largest manufacturers are looking to the U.S. for expanded sales. Story

> The Compounding Shop of St. Petersburg, FL, recalled all of its sterile drugs after an inspection by the FDA found reasons to be concerned about microbial contamination, the FDA said Wednesday. Alert

> The European Medicines Agency (EMA) is following the lead of the U.S. and has a new recommendation to restrict the use of phthalates or parabens as excipients in human drugs. Story

> The government of Malawi, a country in southeast Africa, has helped build a $21 million drug manufacturing plant so that the country will no longer have to import all of its drugs. Story